01 / À propos

PharmaLundensis AB engages in the development of drugs that bind and excrete heavy metals in Sweden. It develops Phal-501 for the treatment of lung diseases COPD and chronic bronchitis. The company was founded in 2006 and is based in Lund, Sweden.